Literature DB >> 12584216

Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study.

M G V M Russel1, B M Ryan, P C Dagnelie, M de Rooij, J Sijbrandij, A Feleus, M Hesselink, J W Muris, R Stockbrugger.   

Abstract

BACKGROUND AND AIMS: The majority of patients with inflammatory bowel disease (IBD) have a normal life expectancy and therefore should not be weighted when applying for life assurance. There is scant literature on this topic. In this study our aim was to document and compare the incidence of difficulties in application for life and medical insurance in a population based cohort of IBD patients and matched population controls.
METHODS: A population based case control study of 1126 IBD patients and 1723 controls. Based on a detailed questionnaire, the frequency and type of difficulties encountered when applying for life and medical insurance in matched IBD and control populations were appraised.
RESULTS: In comparison with controls, IBD patients had an 87-fold increased risk of encountering difficulties when applying for life assurance (odds ratio (OR) 87 (95% confidence interval (CI) 31-246)), with a heavily weighted premium being the most common problem. Patients of high educational status, with continuous disease activity, and who smoked had the highest odds of encountering such problems. Medical insurance difficulties were fivefold more common in IBD patients compared with controls (OR 5.4 (95% CI 2.3-13)) although no specific disease or patient characteristics were identified as associated with such difficulties.
CONCLUSIONS: This is the first detailed case control study that has investigated insurance difficulties among IBD patients. Acquiring life and medical insurance constituted a major problem for IBD patients in this study. These results are likely to be more widely representative given that most insurance companies use international guidelines for risk assessment. In view of the recent advances in therapy and promising survival data on IBD patients, evidence based guidelines for risk assessment of IBD patients by insurance companies should be drawn up to prevent possible discriminatory practices.

Entities:  

Mesh:

Year:  2003        PMID: 12584216      PMCID: PMC1773566          DOI: 10.1136/gut.52.3.358

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

Review 1.  A critical review of epidemiological studies in inflammatory bowel disease.

Authors:  F Farrokhyar; E T Swarbrick; E J Irvine
Journal:  Scand J Gastroenterol       Date:  2001-01       Impact factor: 2.423

2.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

3.  Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England.

Authors:  F Farrokhyar; E T Swarbrick; R H Grace; M D Hellier; A E Gent; E J Irvine
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

4.  Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort.

Authors:  M D Silverstein; E V Loftus; W J Sandborn; W J Tremaine; B G Feagan; P J Nietert; W S Harmsen; A R Zinsmeister
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

5.  Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.

Authors:  E V Loftus; M D Silverstein; W J Sandborn; W J Tremaine; W S Harmsen; A R Zinsmeister
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

6.  Inflammatory bowel disease: costs-of-illness.

Authors:  J W Hay; A R Hay
Journal:  J Clin Gastroenterol       Date:  1992-06       Impact factor: 3.062

7.  Inflammatory bowel disease: medical cost algorithms.

Authors:  A R Hay; J W Hay
Journal:  J Clin Gastroenterol       Date:  1992-06       Impact factor: 3.062

8.  A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions.

Authors:  P Blomqvist; N Feltelius; R Löfberg; A Ekbom
Journal:  Aliment Pharmacol Ther       Date:  2001-04       Impact factor: 8.171

9.  Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.

Authors:  Tine Jess; Karen Vanessa Winther; Pia Munkholm; Ebbe Langholz; Vibeke Binder
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

10.  Survival and causes of death in patients with inflammatory bowel disease: a population-based study.

Authors:  A Ekbom; C G Helmick; M Zack; L Holmberg; H O Adami
Journal:  Gastroenterology       Date:  1992-09       Impact factor: 22.682

View more
  6 in total

Review 1.  Systematic review: The role of race and socioeconomic factors on IBD healthcare delivery and effectiveness.

Authors:  Justin L Sewell; Fernando S Velayos
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

2.  IBD: Trying to optimize a tool to measure disability in IBD.

Authors:  Charles N Bernstein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-09       Impact factor: 46.802

3.  The socio-economic impact of work disability due to inflammatory bowel disease in Brazil.

Authors:  Renata de S B Fróes; Ana Teresa Pugas Carvalho; Antonio Jose de V Carneiro; Adriana Maria Hilu de Barros Moreira; Jessica P L Moreira; Ronir R Luiz; Heitor S de Souza
Journal:  Eur J Health Econ       Date:  2017-05-18

4.  Health concerns associated with travelling with inflammatory bowel disease (IBD): a questionnaire survey.

Authors:  Varun Philip; Anet Soubieres; Andrew Poullis
Journal:  Clin Med (Lond)       Date:  2018-08       Impact factor: 2.659

5.  Travel health and pretravel preparation in the patient with inflammatory bowel disease.

Authors:  Kay Greveson; Thomas Shepherd; John P Mulligan; Mark Hamilton; Sue Woodward; Christine Norton; Charles Murray
Journal:  Frontline Gastroenterol       Date:  2015-04-22

Review 6.  Care of inflammatory bowel disease patients in remission.

Authors:  Charumathi Raghu Subramanian; George Triadafilopoulos
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.